BioLife Solutions appoints Tony J. Hunt (Repligen Chairman) to board effective Jan 2, 2025

BIOLIFE SOLUTIONS INC

Tony J. Hunt, Executive Chairman of Repligen (Nasdaq: RGEN), appointed to BioLife board.
Appointment increases board size to six members; Hunt qualifies as independent under Nasdaq rules.
Hunt previously served as Repligen CEO (2015-2024) and President of Bioproduction at Life Technologies.
He will serve on the Audit Committee and receive standard non-employee director compensation.
Board cites Hunt's bioprocessing expertise to support BioLife's focus on cell and gene therapy tools.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.